AACR
PPH icon

ACR Alpine Capital Research’s VanEck Pharmaceutical ETF PPH Stock Holding History

ACR Alpine Capital Research’s Portfolio PPH Stock Details PPH Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2013
Q3 		– Sell
-277,421
Closed -$12.6M – 21
2013
Q2 		$12.6M Buy
+277,421
New +$12.8M 2.87% 15

Other funds holding PPH

CS
Credit Suisse Zurich, Switzerland $104B AUM 34.76% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
MIM
Macroview Investment Management Bethesda, Maryland $144M AUM 19.29% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
CC
Columbia Capital Fullerton, California $91.6M AUM 27.93% 1-Year Est. Return
MA
Montag & Associates Atlanta, Georgia $2.15B AUM 20.86% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return
MWR
McAdams Wright Ragen Seattle, Washington $1.79B AUM 13.95% 1-Year Est. Return
VF
Virtu Financial New York $2.41B AUM 48.35% 1-Year Est. Return

ACR Alpine Capital Research's PPH Position: Q3 2013 in Review

ACR Alpine Capital Research sold out of VanEck Pharmaceutical ETF (PPH) in Q3 2013, closing a stake of 277,421 shares — an estimated $12.6M sold.

ACR Alpine Capital Research first reported a position in PPH in Q2 2013 and held it in 1 quarter. The position peaked at $12.6M in Q2 2013. 42 funds tracked by Wall St. Rank hold PPH as of Q3 2013.

  • ACR Alpine Capital Research reported no remaining VanEck Pharmaceutical ETF position as of Q3 2013 after selling out during the quarter.
  • ACR Alpine Capital Research sold 277,421 VanEck Pharmaceutical ETF shares in Q3 2013, an estimated $12.6M.
  • ACR Alpine Capital Research first reported a position in VanEck Pharmaceutical ETF in Q2 2013 and held it in 1 quarter.
  • ACR Alpine Capital Research's VanEck Pharmaceutical ETF position peaked at $12.6M in Q2 2013.
  • 42 funds tracked by Wall St. Rank held VanEck Pharmaceutical ETF as of Q3 2013.

Based on ACR Alpine Capital Research's 13F filing for Q3 2013, filed 12 Nov 2013.